Skip to main content

Advertisement

Table 2 Meta-analysis of the APOB rs17240441 polymorphism with plasma APOB and lipid levels

From: Associations of the APOB rs693 and rs17240441 polymorphisms with plasma APOB and lipid levels: a meta-analysis

Groups or subgroups Comparisons (Subjects) P Heterogeneity SMD (95% CI) P SMD
APOB
 All 15 (5047) 0.27 0.13 (0.06–0.20) < 0.01
 Studies in HWE 12 (4192) 0.32 0.11 (0.04–0.19) < 0.01
 Caucasian 8 (3626) 0.31 0.12 (0.03–0.21) < 0.01
 Asian 6 (1264) 0.18 0.14 (−0.01–0.30) 0.07
 CHD 5 (2841) 0.86 0.11 (0.03–0.18) < 0.01
 Healthy or control 9 (1975) 0.06 0.12 (−0.03–0.26) 0.11
 Case-control studies 8 (3951) 0.29 0.13 (0.04–0.21) < 0.01
 Cohort studies 7 (1096) 0.23 0.15 (−0.001–0.30) 0.05
TG
 All 29 (7411) < 0.01 0.03 (−0.04–0.11) 0.37
 Studies in HWE 24 (6576) 0.02 0.04 (−0.05–0.12) 0.44
 Male 6 (3215) 0.14 0.11 (−0.01–0.24) 0.08
 Female 4 (411) 0.16 0.22 (−0.10–0.53) 0.18
 Caucasian 12 (4691) 0.11 0.02 (−0.11–0.07) 0.62
 Asian 11 (1281) 0.13 0.21 (0.06–0.36) < 0.01
 CHD 8 (3138) 0.02 0.15 (−0.01–0.32) 0.07
 Healthy or control 18 (3274) 0.04 −0.02 (−0.13–0.08) 0.70
 Case-control studies 15 (4538) 0.12 0.09 (−0.003–0.18) 0.06
 Cohort studies 14 (2873) 0.03 0.03 (−0.04–0.11) 0.60
TC
 All 32 (7875) < 0.01 0.17 (0.07–0.26) < 0.01
 Studies in HWE 23 (6133) < 0.01 0.18 (0.04–0.33) 0.01
 Male 7 (3220) 0.72 0.14 (0.07–0.21) < 0.01
 Female 5 (470) < 0.01 0.74 (−0.26–1.75) 0.15
 Caucasian 14 (4598) 0.34 0.13 (0.06–0.20) < 0.01
 Asian 13 (1924) < 0.01 0.33 (0.06–0.60) 0.02
 CHD 10 (3455) 0.42 0.12 (0.05–0.19) < 0.01
 Healthy or control 15 (2577) < 0.01 0.23 (0.05–0.40) 0.01
 Case-control studies 14 (4526) < 0.01 0.22 (0.03–0.41) 0.02
 Cohort studies 18 (3349) 0.15 0.14 (0.05–0.23) < 0.01
LDL-C
 All 30 (5658) < 0.01 0.15 (0.07–0.23) < 0.01
 Studies in HWE 23 (4233) < 0.01 0.15 (0.04–0.25) < 0.01
 Male 5 (955) 0.85 0.07 (−0.06–0.21) 0.27
 Female 4 (411) 0.04 0.01 (−0.38–0.41) 0.95
 Caucasian 13 (2562) 0.38 0.14 (0.05–0.23) < 0.01
 Asian 12 (1817) < 0.01 0.18 (0.00–0.35) 0.05
 CHD 7 (879) 0.09 0.15 (−0.04–0.34) 0.12
 Healthy or control 19 (3764) < 0.01 0.13 (0.02–0.24) 0.02
 Case-control studies 15 (2807) 0.07 0.12 (0.02–0.23) 0.03
 Cohort studies 15 (2851) < 0.01 0.18 (0.06–0.31) < 0.01
HDL-C
 All 27 (5124) < 0.01 −0.04 (−0.12–0.05) 0.40
 Studies in HWE 21 (3750) < 0.01 −0.07 (−0.18–0.05) 0.25
 Male 5 (703) 0.10 −0.06 (−0.30–0.17) 0.58
 Female 4 (411) 0.57 −0.01 (−0.23–0.21) 0.91
 Caucasian 9 (1881) 0.30 −0.02 (−0.13–0.09) 0.77
 Asian 13 (1924) < 0.01 −0.10 (−0.26–0.06) 0.21
 CHD 7 (879) 0.05 −0.06 (−0.27–0.14) 0.55
 Healthy or control 18 (3605) 0.01 −0.03 (−0.13–0.08) 0.65
 Case-control studies 13 (2267) 0.02 −0.07 (−0.20–0.06) 0.31
 Cohort studies 14 (2854) 0.06 −0.01 (−0.12–0.10) 0.89
  1. SMD standardized mean difference, 95% CI 95% confidence interval, HWE Hardy-Weinberg equilibrium, APOB apolipoprotein B, TG triglyceride, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol